Template talk:PPAR modulators
 | This template does not require a rating on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
Sorry Ibuprofen, but I don't think you qualify as a PPAR Modulator
editOne in-vitro study determined that ibuprofen at 500μM induced lipogenesis, the main hallmark of PPARγ activation, 100μM had no effect; 500μM translates to an oral dose in the ballpark of 3,100mg—is this effect relevant enough to include in this template?
Indomethacin with 80μM as the lipogenic dose translates to doses far exceeding 1,000mg—another super-therapeutic dose.
In that study, the method for determining agonist efficacy is questionable—it does not assess PPARγ with its RXRα coactivator, hence ibuprofen could in fact be a weak partial agonist when paired with RXRα—which is why I'm ignoring it.
Pleased to hear additional information, but at this point I'm very tempted to remove this potentially misinformed item. Insect.eate (talk) 00:35, 10 October 2024 (UTC)
- Correction: Ibuprofen is sometimes administered in doses of 800mg 4 times daily, quite possibly enough for PPARγ effects to manifest. I don't know what to do here, input from others is appreciated—I'm not sure whether items in templates are supposed to be clinically relevant examples, or whether tentative in-vitro evidence is enough for inclusion.
- If it's the latter, NSAIDs like indomethacin and naproxen should possibly be included alongside ibuprofen. Insect.eate (talk) 05:44, 12 October 2024 (UTC)